Biotech IV Monitor

SLS — SELLAS Life Sciences Group Inc.

$2.1B market cap · 1 upcoming readout tracked

Clinical trial readout dates for SELLAS Life Sciences Group Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts1none in Phase 3
Market cap$2.1B
Cash & investments$135M~13 quarters at last loss rate
Recent 8-K filings2latest 2026-11-17

Upcoming readouts

Phase 1/2 SLS009
Hematologic Malignancies · NCT04588922
December 2026
Recruiting

Cash position

SELLAS Life Sciences Group Inc. reported $135M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-12). Its net loss for that quarter was $10M; at that rate the cash would last about 13 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-17
8-K Results of Operations — earnings, may carry pipeline updates2026-11-12

Companies working on similar indications

Discussion

No messages yet. If you follow SLS, you can start the conversation.
Track SLS in real time
See live implied volatility for SLS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on SLS
Contact — questions or corrections about SLS: dukeupt@gmail.com